Related Experiment Video
Updated: Jan 6, 2026
11:39
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
Published on: October 23, 2019
12.1K
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma
Edward R Scheffer Cliff1,2, Guido D Pelaez3, Fei Wan4
1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Summary
Polatuzumab vedotin shows greater efficacy in non-germinal center B-cell (GCB) large B-cell lymphoma (LBCL) when used in relapsed/refractory settings. Immunohistochemistry-based cell of origin (COO) classification predicts treatment response, guiding clinical decisions for LBCL patients.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Polatuzumab vedotin (polatuzumab) is approved for front-line diffuse large B-cell lymphoma (DLBCL) treatment (Pola-R-CHP).
- Efficacy of polatuzumab may differ between activated B-cell and germinal center B-cell (GCB) subtypes.
- Routine clinical practice uses immunohistochemistry (Hans algorithm) for cell of origin (COO) assessment, unlike research RNA expression methods.
Purpose of the Study:
- To evaluate the impact of immunohistochemistry-based COO on polatuzumab efficacy in large B-cell lymphoma (LBCL).
- To compare polatuzumab effectiveness in first-line versus relapsed/refractory LBCL settings, stratified by COO.
Main Methods:
- Multicenter real-world study of 740 adult LBCL patients treated with polatuzumab (2015-2024).
- Patients categorized into first-line (305) and relapsed/refractory (435) cohorts.
- Primary endpoint: Overall Response Rate (ORR) in relapsed/refractory GCB vs. non-GCB LBCL.
Main Results:
- In relapsed/refractory LBCL, ORR was significantly higher in non-GCB (59.7%) vs. GCB (36.3%) COO (P < 0.0001).
- Complete response rates and progression-free survival also favored non-GCB COO in the relapsed/refractory setting.
- First-line treatment showed similar outcomes across COO subtypes, suggesting polatuzumab overcomes non-GCB disadvantage with R-CHOP.
Conclusions:
- Immunohistochemistry-based COO classification (Hans algorithm) is a significant predictor of polatuzumab efficacy in LBCL.
- Findings support using COO to guide real-world treatment decisions for LBCL patients receiving polatuzumab.
